查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1578307

全球抗凝血剂市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Anticoagulant Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

预计全球抗凝血剂市场需求将从2023年的401亿美元增加至2032年的近899.5亿美元，2024-2032年研究期间复合年增长率为9.39%。

抗凝血剂，通常称为血液稀释剂，是阻止或减少血液凝固并延长凝血时间的化学物质。抗凝血剂用于消除体内血栓的机会。当血小板黏合在一起并且血液中存在的蛋白质结合在一起形成固体块时，就会形成血栓。抗凝血剂阻止血小板相互结合并阻止凝血蛋白黏附在一起。市面上提供各种类型的抗凝血药物，每种药物都透过阻止各种血液凝固途径发挥作用。这些药物主要用于治疗高危险血栓、深部静脉栓塞、肺栓塞等。此外，它们也常用于治疗肺栓塞、心房颤动和控制中风风险。

市场动态

随着全球静脉血栓栓塞和心血管疾病等疾病的增加，全球抗凝血剂市场预计在未来几年将大幅成长。此外，新型口服抗凝血剂的日益采用以及对新技术的认识的成熟正在推动市场成长。同样，随着对现代治疗方法的需求不断增长，肥胖问题和老年人口的扩大预计将影响预测期内全球抗凝血药物市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球抗凝血剂市场的每个细分市场进行了包容性评估。抗凝血产业的成长和趋势为本研究提供了整体方法。

市场区隔

抗凝血剂市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按药品类别

  • 新型口服抗凝血剂 (NOAC)（Eliquis、Xarelto、Savaysa & Lixiana、Pradaxa）
  • 维生素K拮抗剂
  • 直接凝血酶抑制剂
  • 肝素和低分子肝素 (LMWH)
  • 其他的

依给药途径

  • 口服抗凝血剂
  • 注射抗凝血剂

按申请

  • 心房颤动/心肌梗塞（心臟病发作）
  • 深部静脉血栓 (DVT)
  • 肺栓塞
  • 其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲抗凝血剂市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。抗凝血剂市场的主要参与者包括阿斯彭控股公司、辉瑞公司、百时美施贵宝公司、葛兰素史克公司、赛诺菲公司、拜耳公司、勃林格殷格翰国际有限公司、第一三共有限公司、强生服务公司、卫材有限公司本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来能力、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：抗凝血剂 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按药品类别分類的市场吸引力分析
    • 按给药途径进行的市场吸引力分析
    • 市场吸引力分析：依应用分类
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球抗凝血剂市场分析：按药物类别

  • 按药物类别概述
  • 历史和预测数据
  • 按药物类别分析
  • 新型口服抗凝血剂 (NOAC)（Eliquis、Xarelto、Savaysa & Lixiana、Pradaxa）
  • 维生素K拮抗剂
  • 直接凝血酶抑制剂
  • 肝素和低分子肝素 (LMWH)
  • 其他的

第 6 章：全球抗凝血剂市场分析：依给药途径

  • 依给药途径概述
  • 历史和预测数据
  • 依给药途径分析
  • 口服抗凝血剂
  • 注射抗凝血剂

第 7 章：全球抗凝血剂市场分析：按应用分类

  • 概述：按应用
  • 历史和预测数据
  • 分析：按应用
  • 心房颤动/心肌梗塞（心臟病发作）
  • 深部静脉血栓 (DVT)
  • 肺栓塞
  • 其他的

第 8 章：全球抗凝血剂市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 9 章：抗凝血剂公司的竞争格局

  • 抗凝血药市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 10 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Aspen Holdings
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bristol-Myers Squibb Company
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • GSK Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sanofi
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bayer AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Boehringer Ingelheim International GmbH
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Daiichi Sankyo Company Limited
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Johnson & Johnson Services Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Eisai Co. Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11211613

The global demand for Anticoagulant Market is presumed to reach the market size of nearly USD 89.95 Billion by 2032 from USD 40.1 Billion in 2023 with a CAGR of 9.39% under the study period 2024-2032.

Anticoagulants, generally called blood thinners, are chemical materials that prohibit or curtail coagulation of blood and lengthen the clotting period. Anticoagulants are used to abolish the chances of blood clots in the body. Blood clots are built when platelets glue together and proteins present in the blood bind together to create a solid lump. Anticoagulants cease the platelets from binding to one another and clotting proteins from adhering together. The market offers various types of anticoagulant drugs, and each drug functions by deterring various paths of blood coagulation. These drugs are primarily used for the high threat of blood clots, deep vein thrombosis, pulmonary embolism, and others. Besides, they are commonly used in the treatment of pulmonary embolism, atrial fibrillation, and managing the risk of stroke.

MARKET DYNAMICS

The global anticoagulants market is anticipated to grow at a substantial rate in the coming years, with the increasing plurality of diseases such as venous thromboembolism and cardiovascular disease across the globe. Moreover, the growing adoption of new oral anticoagulants, and maturing awareness of new techniques is boosting the market growth. Similarly, expanding obesity problems and geriatric population with the growing demand for contemporary therapeutics are predicted to affect the growth of the global anticoagulant market during the forecast period.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anticoagulant. The growth and trends of Anticoagulant industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Anticoagulant market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Category

  • Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa)
  • Vitamin K Antagonist
  • Direct Thrombin Inhibitors
  • Heparin and Low Molecular Weight Heparin (LMWH)
  • Others

By Route of Administration

  • Oral Anticoagulants
  • Injectable Anticoagulants

By Application

  • Atrial Fibrillation/Myocardial Infarction (Heart Attack)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Anticoagulant market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anticoagulant market include Aspen Holdings, Pfizer Inc., Bristol-Myers Squibb Company, GSK Plc, Sanofi, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Eisai Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ANTICOAGULANT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Category
    • 3.7.2 Market Attractiveness Analysis By Route of Administration
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY DRUG CATEGORY

  • 5.1. Overview By Drug Category
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Drug Category
  • 5.4. Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa) Historic and Forecast Sales By Regions
  • 5.5. Vitamin K Antagonist Historic and Forecast Sales By Regions
  • 5.6. Direct Thrombin Inhibitors Historic and Forecast Sales By Regions
  • 5.7. Heparin and Low Molecular Weight Heparin (LMWH) Historic and Forecast Sales By Regions
  • 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route of Administration
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Route of Administration
  • 6.4. Oral Anticoagulants Historic and Forecast Sales By Regions
  • 6.5. Injectable Anticoagulants Historic and Forecast Sales By Regions

7. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY APPLICATION

  • 7.1. Overview By Application
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Application
  • 7.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack) Historic and Forecast Sales By Regions
  • 7.5. Deep Vein Thrombosis (DVT) Historic and Forecast Sales By Regions
  • 7.6. Pulmonary Embolism Historic and Forecast Sales By Regions
  • 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ANTICOAGULANT COMPANIES

  • 9.1. Anticoagulant Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF ANTICOAGULANT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Aspen Holdings
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Pfizer Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Bristol-Myers Squibb Company
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. GSK Plc
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Sanofi
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Bayer AG
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Boehringer Ingelheim International GmbH
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Daiichi Sankyo Company Limited
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Johnson & Johnson Services Inc.
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Eisai Co. Ltd
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Category (USD MN)
  • Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa) Market Sales By Geography (USD MN)
  • Vitamin K Antagonist Market Sales By Geography (USD MN)
  • Direct Thrombin Inhibitors Market Sales By Geography (USD MN)
  • Heparin and Low Molecular Weight Heparin (LMWH) Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Anticoagulants Market Sales By Geography (USD MN)
  • Injectable Anticoagulants Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Atrial Fibrillation/Myocardial Infarction (Heart Attack) Market Sales By Geography (USD MN)
  • Deep Vein Thrombosis (DVT) Market Sales By Geography (USD MN)
  • Pulmonary Embolism Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Anticoagulant Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Anticoagulant Report
  • Market Research Process
  • Market Research Methodology
  • Global Anticoagulant Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Category
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Category (USD MN)
  • Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa) Market Sales By Geography (USD MN)
  • Vitamin K Antagonist Market Sales By Geography (USD MN)
  • Direct Thrombin Inhibitors Market Sales By Geography (USD MN)
  • Heparin and Low Molecular Weight Heparin (LMWH) Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Anticoagulants Market Sales By Geography (USD MN)
  • Injectable Anticoagulants Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Atrial Fibrillation/Myocardial Infarction (Heart Attack) Market Sales By Geography (USD MN)
  • Deep Vein Thrombosis (DVT) Market Sales By Geography (USD MN)
  • Pulmonary Embolism Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.